Surrogates are just surrogates, but helpful just the same by Fabian, Carol
What is a surrogate end-point biomarker?
A surrogate end-point biomarker (SEB) may broadly be
defined as a predictive measure of a future outcome. For
individuals without evidence of cancer, a risk biomarker
predicts clinical disease onset. In the case of established
cancer, a risk biomarker predicts recurrence or progression.
A response biomarker is usually a reversible risk biomarker
that predicts disease prevention or, in the case of established
cancer, eradication or temporary control.
Properties of surrogate end-point biomarkers
To be credible, an SEB must have biological plausibility and a
strong association with ultimate outcome. To be used for
prevention, an SEB should be identified as being causally
related to the development of precancer and cancer.
Modulation of the SEB through an intervention should predict
outcome. The SEB should be reproducible and reliable.
Reproducibility is generally maximized with a quantitative
biomarker. Optimally, both risk and response SEBs should be
prospectively validated in a clinical trial in which the
nonsurrogate outcome is also being evaluated [1,2].
Uses of surrogate markers in cancer treatment
SEBs are used in clinical trials to identify effective new strate-
gies faster and more economically with fewer patients. They may
also offer insight into why or why not a particular therapy does
not work. In the patient care setting, SEBs are used to
determine whether and when to change the therapeutic plan.
In the metastatic setting, typically the same surrogate markers
are measured repeatedly to assess response or progression
often by imaging and/or physical examination. Two surrogate
markers can independently predict the same outcome, but
results at any single point in time may be discordant.
Consequently, it is important to understand the biology that
underlies the surrogate in order to avoid making inappropriate
clinical decisions.
In the neoadjuvant setting, a low Ki-67 a few weeks after
initiation of treatment and pathological response after several
months of treatment both predict long-term disease-free
survival [3-5]. Both biomarkers are currently used in the
research setting, and pathological stage after neoadjuvant
treatment is used clinically to estimate distant disease-free
survival. It is probable that, in the near future, early reduction
in breast proliferation will be used along with clinical indices
to determine whether to switch antihormonal or chemothera-
peutic treatment during the neoadjuvant period. Pathological
response after neoadjuvant chemotherapy will also probably
be used to determine whether to administer additional
chemotherapy adjuvantly to women with hormone receptor
negative tumours (Figure 1).
Use of surrogate markers in cancer
prevention
Perhaps the greatest need for surrogate biomarkers is in the
prevention setting, where the traditionally measured outcome
of cancer occurs infrequently and only after a long latent
period. Biomarkers that accurately predict short-term risk are
needed in order to avoid treating healthy women with drugs
tthat most do not need in order to benefit a few. Reversible
risk biomarkers could be used to monitor response for those
individuals undergoing the intervention.
Prevention risk biomarkers
Serum levels of insulin-like growth factor (IGF)-1, the ratio of
IGF-1 to its binding protein IGFBP-3, serum luteal phase
progesterone and free testosterone in premenopausal
women, and prolactin and bioavailable oestradiol and testos-
terone in postmenopausal women are examples of risk
biomarkers that can be measured with a simple blood test
[6]. However, the two biomarkers associated with the
greatest relative risk for invasive cancer and likely to be most
reflective of events at the level of the breast are
mammographic density and intraepithelial neoplasia.
Mammographic density is reflective of the amount of stroma,
epithelium and fluid in the breast relative to fat. There are both
qualitative and quantitative means of measuring mammo-
graphic density [7,8]. Using the computer-assisted method of
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increased density have an approximate fivefold increase in
risk relative to those with no increased density (that is, a
completely fatty breast). Mammographic density has been
shown to increase modestly the concordance statistic
associated with Gail model predicted probability, and thus it
should improve the accuracy of individual risk estimates
[9,10]. The advantages of mammographic density as an SEB
is that it is quantitative, positively associated with some risk
factors (including benign breast disease, and oestrogen and
progestin combined hormone replacement therapy [11,12])
and can be obtained at minimal extra cost and with no extra
procedure in screened women.
The disadvantages are that it is negatively correlated with
some risk factors, including age and obesity, and may be
negatively correlated with free oestradiol. There is substantial
technical and interpretive variance, and it is unclear whether
effective agents such as tamoxifen and raloxifene reduce
density in postmenopausal women over 55 years old [13-16].
Cuzick and coworkers [15] suggested that reduction in
density is associated with only one-third of the risk reduction
resulting from tamoxifen administration.
It is quite possible that density results from the interplay of
stromal and epithelial mitogens such as IGF-1, oestrogen and
progestin, such that if one or more of the factors is low at
baseline and/or is unaffected by the prevention intervention,
then no change may occur in density, although risk may be
diminished.
Intraepithelial neoplasia obtained by
nonlesion directed sampling
The findings of hyperplasia and atypical hyperplasia in a
diagnostic biopsy are associated with an approximate twofold
and fivefold subsequent increase in risk for breast cancer,
respectively [6]. Because most women have not had a
diagnostic biopsy, another method is required to obtain
tissue for risk stratification and for monitoring a prevention
intervention.
Both nipple aspirate fluid (NAF) and random periareolar fine
needle aspiration (RPFNA) evidence of atypia have been
shown to increase the concordance statistic based on the
Gail model [17-19]. NAF harvest is noninvasive and
inexpensive, but the majority of NAF samples have no or few
cells whereas more than 90% of RPFNA samples are cellular
[17]. The advantages of breast tissue sampling by RPFNA for
risk and response biomarkers is that it provides a direct
assessment of precancerous change as well as tissue for
other response and predictive markers such as Ki-67 and
oestrogen receptor (ER), and there is minimal discomfort.
Disadvantages are that it does involve a procedure that
requires training, and there is both intra- and inter-observer
interpretive variance.
Use of breast density and breast tissue
biomarkers in phase II prevention trials
Arzoxifene is a third-generation selective oestrogen receptor
modulator (SERM) similar to raloxifene but with greater
potency, primarily because of greater bioavailability. We
assessed the effect of 6 months of arzoxifene compared with
placebo on several risk biomarkers as part of a multi-
institutional National Cancer Institute sponsored phase II
prevention trial [20]. Compared with placebo, there was no
change in cytomorphology index score, but there was a
significant favorable modulation of mammographic breast
density, breast tissue ER expression and serum IGF-1/
IGFBP-3 ratio. These changes were more marked in pre-
menopausal than in postmenopausal women. Arzoxifene is
being further assessed in a phase III prevention trial with
incidence of bone fracture and breast cancer as two co-
primary end-points.
From the arzoxifene phase II trial we learned that change in
biomarker expression may vary with menopause status and
that cytomorphology change is not a sensitive indicator of
SERM bioactivity after short-term administration. Expression
of Ki-67 and ER increase with morphological abnormality in
benign breast tissue whether sampled by diagnostic biopsy
or RPFNA [21-23]. Consequently, changes in Ki-67 and ER
expression were explored as end-points for phase II trials with
antihormonal agents in our trial of letrozole in high-risk women
on HRT. Ki-67 is also higher in premenopausal than in
postmenopausal women [22]. The concept of using letrozole
in high-risk women taking hormone replacement therapy
(HRT) has been shown to be valid in hormonally intact
aromatase over-expressing mice [24]. Postmenopausal
women produce the majority of breast oestrogen locally via
aromatase and sulfatase [25] and aromatase activity is
increased in precancerous breast tissue [26].
We found a significant decrease in benign breast tissue Ki-
67 (mean 5.1% at baseline and 1.5% after 6 months of
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Figure 1
Surrogate response biomarkers will guide neoadjuvant treatment. ER,
oestrogen receptor; pCR, pathological complete response; PR,
progesterone receptor; Rx, treatment.Available online http://breast-cancer-research.com/content/9/S2/S18
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letrozole) in 42 high-risk women on a stable dose of hormone
replacement. There was no significant accompanying change
in serum oestradiol, IGF-1, the IGF-1/IGFBP-3 ratio, or
mammographic breast density [27]. Cytomorphology desig-
nation was likewise unchanged after 6 months of letrozole,
although the proportion of abnormal cells in the specimens by
karyometry was reduced from baseline [28]. Given our pilot
study results, the concept of utilizing letrozole to reduce
breast cancer risk in women on HRT is being tested further in
a multi-institutional placebo controlled trial sponsored by the
US National Cancer Institute.
Conclusion
Modulation of an individual surrogate response biomarker is
likely to be dramatically influenced by agent, menopause
status and baseline characteristics of the cohort (Table 1).
Biomarkers are extremely valuable in initial testing of new
strategies, particularly in prevention. However, it is important
to understand how the agents may differentially modulate risk
biomarkers, so that an effective agent is not discarded
because it does not favourably modulate all risk biomarkers.
Currently, response biomarkers for prevention are utilized
only within the context of phase I and II trials. Surrogate
markers in metastatic disease and in the neoadjuvant arena
are helpful both for research and in clinical decision making.
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